Most cited papers in Hepatitis Viruses Studies and Epidemiology
What are the most cited papers in Hepatitis Viruses Studies and Epidemiology?
The most cited paper in Hepatitis Viruses Studies and Epidemiology is "Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial" (Michael Peter Manns, John G. McHutchison, Stuart C. Gordon et al., 2001), with 6,056 citations. Next come "Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C" (3,509) and "Expanding consensus in portal hypertension" (3,103).
Showing 50 of 100 papers. Every paper with more than 659 citations is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Michael Peter Manns, John G. McHutchison, Stuart C. Gordon et al. · The Lancet | Sep 2001 | 6,056 |
| 2 | Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C John G. McHutchison, Stuart C. Gordon, Eugene R. Schiff et al. · New England Journal of Medicine | 19 Nov 1998 | 3,509 |
| 3 | Expanding consensus in portal hypertension Roberto de Franchis · Journal of Hepatology | 5 Jun 2015 | 3,103 |
| 4 | Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis C Stephanos J. Hadziyannis, Hoel Sette, Timothy R. Morgan et al. · Annals of Internal Medicine | 2 Mar 2004 | 2,842 |
| 5 | Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013 Aparna Schweitzer, Johannes Horn, Rafael Mikolajczyk et al. · The Lancet | 28 Jul 2015 | 2,802 |
| 6 | Hepatitis B Virus Infection William M. Lee · New England Journal of Medicine | 11 Dec 1997 | 2,588 |
| 7 | The Global Burden of Nontyphoidal Salmonella Gastroenteritis Shannon Elizabeth Majowicz, Jennie Musto, Elaine Scallan et al. · Clinical Infectious Diseases | 16 Feb 2010 | 2,497 |
| 8 | Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus Thierry Poynard, Patrick Marcellin, Samuel S. Lee et al. · The Lancet | Oct 1998 | 2,335 |
| 9 | Revising consensus in portal hypertension: Report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension Roberto de Franchis · Journal of Hepatology | 2 Jul 2010 | 2,300 |
| 10 | Portal hypertensive bleeding in cirrhosis Guadalupe García–Tsao, Juan G. Abraldeṣ, Annalisa Berzigotti et al. · Hepatology | 16 Nov 2016 | 2,153 |
| 11 | Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study Sarah Blach et al. · The Lancet. Gastroenterology & hepatology | 15 Dec 2016 | 2,049 |
| 12 | Global Illness and Deaths Caused by Rotavirus Disease in Children Umesh D. Parashar, Erik Hummelman, Joseph Bresee et al. · Emerging infectious diseases | May 2003 | 1,907 |
| 13 | Global epidemiology of hepatitis B virus infection: New estimates of age-specific HBsAg seroprevalence and endemicity Jördis Jennifer Ott, Gretchen A Stevens, Justina L. Groeger et al. · Vaccine | 29 Jan 2012 | 1,868 |
| 14 | A One-Year Trial of Lamivudine for Chronic Hepatitis B Ching‐Lung Lai, Rong‐Nan Chien, Nancy W.Y. Leung et al. · New England Journal of Medicine | 9 Jul 1998 | 1,763 |
| 15 | Immunology of hepatitis B virus and hepatitis C virus infection Barbara Rehermann, Michelina Nascimbeni · Nature reviews. Immunology | Mar 2005 | 1,641 |
| 16 | The Natural History of Community-Acquired Hepatitis C in the United States Miriam J. Alter, Harold S. Margolis, Krzysztof Krawczynski et al. · New England Journal of Medicine | 31 Dec 1992 | 1,615 |
| 17 | Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral Load Uchenna H. Iloeje, Hwai‐I Yang, Jun Su et al. · Gastroenterology | Mar 2006 | 1,541 |
| 18 | Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B George K.K. Lau, Teerha Piratvisuth, Kang Luo et al. · New England Journal of Medicine | 29 Jun 2005 | 1,527 |
| 19 | A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B Ting‐Tsung Chang, Robert G. Gish, Robert de Man et al. · New England Journal of Medicine | 8 Mar 2006 | 1,450 |
| 20 | Molecular Cloning and Disease Association of Hepatitis G Virus: A Transfusion-Transmissible Agent Jeff Linnen et al. · Science | 26 Jan 1996 | 1,390 |
| 21 | The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013 Jeffrey D Stanaway et al. · The Lancet | 7 Jul 2016 | 1,388 |
| 22 | Hepatitis E Virus and Chronic Hepatitis in Organ-Transplant Recipients Nassim Kamar, Janick Sèlves, Jean‐Michel Mansuy et al. · New England Journal of Medicine | 20 Feb 2008 | 1,353 |
| 23 | Interferon Alfa-2b Alone or in Combination with Ribavirin for the Treatment of Relapse of Chronic Hepatitis C Gary L. Davis, Rafael Esteban, Vinod K. Rustgi et al. · New England Journal of Medicine | 19 Nov 1998 | 1,299 |
| 24 | Vaccination greatly reduces disease, disability, death and inequity worldwide André Fe, Robert Booy, H.L. Bock et al. · Bulletin of the World Health Organization | 7 Jan 2008 | 1,277 |
| 25 | Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Karen L. Kotloff, Jonathan P. Winickoff, Bernard Ivanoff et al. · PubMed | 1999 | 1,263 |
| 26 | Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance Agustı́n Albillos, Margaret Lario, Melchor Álvarez‐Mon · Journal of Hepatology | 15 Aug 2014 | 1,253 |
| 27 | Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation Francisco M. Marty et al. · New England Journal of Medicine | 6 Dec 2017 | 1,244 |
| 28 | Hepatitis B virus infection Yun‐Fan Liaw, Chia‐Ming Chu · The Lancet | Feb 2009 | 1,223 |
| 29 | Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B Ching‐Lung Lai, Daniel Shouval, Anna S. Lok et al. · New England Journal of Medicine | 8 Mar 2006 | 1,196 |
| 30 | Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial Harry L.A. Janssen, Monika van Zonneveld, Hakan Şentürk et al. · The Lancet | 2005 | 1,165 |
| 31 | Hepatitis B Virus Infection: Epidemiology and Vaccination Colin W. Shepard · Epidemiologic Reviews | Jun 2006 | 1,162 |
| 32 | A novel virus in swine is closely related to the human hepatitis E virus Xiang‐Jin Meng, Robert H. Purcell, Patrick G. Halbur et al. · Proceedings of the National Academy of Sciences | 2 Sep 1997 | 1,156 |
| 33 | Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B Patrick Marcellin, George K.K. Lau, Ferruccio Bonino et al. · New England Journal of Medicine | 15 Sep 2004 | 1,149 |
| 34 | Isolation of novel virus-like sequences associated with human hepatitis John N. Simons, Thomas P. Leary, George J. Dawson et al. · Nature Medicine | Jun 1995 | 1,148 |
| 35 | A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. Eric E. Mast, Cindy M. Weinbaum, Anthony E. Fiore et al. · PubMed | 8 Dec 2006 | 1,137 |
| 36 | Typhoid Fever Christopher Martin Parry, Tran Tinh Hien, Gordon Dougan et al. · New England Journal of Medicine | 27 Nov 2002 | 1,134 |
| 37 | HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS) Chloe L. Thio, Eric C. Seaberg, Richard L. Skolasky et al. · The Lancet | Dec 2002 | 1,099 |
| 38 | Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection John G. McHutchison, Gregory T. Everson, Stuart C. Gordon et al. · New England Journal of Medicine | 29 Apr 2009 | 1,090 |
| 39 | The Natural History of Hepatitis C Virus Infection David Lee Thomas, Jacquie A. Astemborski, Rudra M. Rai et al. · JAMA | 26 Jul 2000 | 1,081 |
| 40 | Hepatitis E virus (HEV): Molecular cloning and sequencing of the full-length viral genome Albert W. Tam, Matthew M. Smith, M. Guerra et al. · Virology | Nov 1991 | 1,065 |
| 41 | Liver Transplantation in European Patients with the Hepatitis B Surface Antigen Didier Samuel, Rainer T. Müller, Graeme Alexander et al. · New England Journal of Medicine | 16 Dec 1993 | 1,054 |
| 42 | VIRUS-LIKE PARTICLES IN SERUM OF PATIENTS WITH AUSTRALIA-ANTIGEN-ASSOCIATED HEPATITIS D. Surrey Dane, C.H. Cameron, Moya Briggs · The Lancet | Apr 1970 | 1,049 |
| 43 | Evolving Consensus in Portal Hypertension Report of the Baveno IV Consensus Workshop on methodology of diagnosis and therapy in portal hypertension Roberto de Franchis · Journal of Hepatology | Jun 2005 | 1,032 |
| 44 | Vaccine Refusal, Mandatory Immunization, and the Risks of Vaccine-Preventable Diseases Saad B. Omer, Daniel A. Salmon, Walter Albert Orenstein et al. · New England Journal of Medicine | 6 May 2009 | 1,023 |
| 45 | Epidemiology of viral hepatitis and HIV co-infection Miriam J. Alter · Journal of Hepatology | 22 Nov 2005 | 1,018 |
| 46 | Epidemiological serosurvey of Hepatitis B in China—Declining HBV prevalence due to Hepatitis B vaccination Xiaofeng Liang et al. · Vaccine | 2 Sep 2009 | 1,010 |
| 47 | Acute liver failure William E. Bernal, Georg M. Auzinger, Anil Dhawan et al. · The Lancet | Jul 2010 | 1,002 |
| 48 | Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B David Ka Ki Wong, Angela M. Cheung, Keith O'Rourke et al. · Annals of Internal Medicine | 15 Aug 1993 | 1,002 |
| 49 | Zoonotic transmission of hepatitis E virus from deer to human beings Shuchin Tei, Naoto Kitajima, Kazuaki Takahashi et al. · The Lancet | Aug 2003 | 973 |
| 50 | Systematic Literature Review of Role of Noroviruses in Sporadic Gastroenteritis Manish M Patel, Marc‐Alain Widdowson, Roger I. Glass et al. · Emerging infectious diseases | Aug 2008 | 969 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for a field when OpenAlex files it under one of the field's topics; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.